Cloud-Clone pushes 17,000 recombinant proteins for research and biomanufacturing

Cloud-Clone Corp. says it now offers more than 17,000 recombinant protein products for academic research and industrial use, backed by GMP-compliant production and multi-step quality checks. The company is positioning the catalog as a way to speed drug discovery, protein validation and large-scale biomanufacturing.

Why it matters: - Cloud-Clone is targeting two bottlenecks at once: access to high-quality research proteins and reliable supply for biomanufacturing. - The company says its catalog is designed to support everything from basic lab work to pharmaceutical development. - Broad species coverage and validated activity data can reduce custom development time and experimental delays.

What happened: - Cloud-Clone Corp. said it has built a portfolio of more than 17,000 recombinant protein products. - The announcement says the lineup spans more than 2,900 full-length proteins and more than 1,300 biologically active proteins. - The catalog covers more than 10 species, including human, mouse, rat, guinea pig, rabbit, canine, porcine, bovine and goat proteins. - The company framed the release as a one-stop protein solution for research institutions and pharmaceutical companies worldwide.

The details: - The product mix includes cytokines, growth factors, neurotrophic factors, enzymes, receptor proteins and tumor biomarkers. - Cloud-Clone also says the catalog includes rare specialized research proteins. - The proteins are produced on the company’s self-developed expression platforms. - Cloud-Clone says the workflow runs from gene sequence design through purification under full internal control and traceability. - The company says purity is at least 95%, verified by SDS-PAGE and HPLC. - The company says endotoxin levels stay below 0.01 EU/μg. - Functional testing covers stimulatory activity, binding activity and enzymatic activity. - Every product ships with a Certificate of Analysis and complete testing datasets. - Manufacturing follows GMP cleanroom standards. - Cloud-Clone says its industrial-scale output supports bulk deliveries from milligram to gram quantities. - The company says its expression systems include prokaryotic platforms and eukaryotic systems such as yeast, insect cells, HEK293 and CHO cells. - Custom services cover expression system selection, fusion tag design and functional activity validation. - A technical team is available to handle hard-to-produce targets and complex proteins.

Between the lines: - The pitch is as much about trust as volume. - Multi-step validation, low endotoxin levels and GMP-style production are aimed at customers who need reproducibility for sensitive assays and downstream development. - The company is also signaling that it wants to compete beyond research reagents and into supply chains for industrial production. - Cloud-Clone says its proteins have supported tens of thousands of peer-reviewed SCI papers and have appeared in journals including Nature, Cell, Nature Nanotechnology and Signal Transduction and Targeted Therapy.

What's next: - Cloud-Clone says it will keep expanding its protein engineering work, product portfolio and technical services. - The company is also aiming to raise quality benchmarks and broaden support for global life science and biomanufacturing customers. - The announcement suggests future growth will focus on more custom development and larger-scale production capacity.

The bottom line: - Cloud-Clone is betting that breadth, validation and manufacturing discipline will make its recombinant proteins a default option for both academic labs and pharmaceutical developers.